Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

Credit: Business Wire- Published on May 16, 2019
LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$CNCElt;/agt; lt;a href="" target="_blank"gt;#CNCElt;/agt;--Concert initiated a second open label clinical trial to evaluate once-daily vs. twice-daily oral dosing of CTP-543 in patients with alopecia areata.

You are here

You might like